CG Oncology, Inc. (NASDAQ:CGON - Get Free Report)'s stock price fell 8.7% during trading on Tuesday. The stock traded as low as $75.44 and last traded at $77.3750. Approximately 376,593 shares changed hands during trading, a decline of 67% from the average daily volume of 1,139,290 shares. The stock had previously closed at $84.78.
Key CG Oncology News
Investors following CGON have been watching these news items:
- Positive Sentiment: Analyst price targets moved higher on Nov. 17: HC Wainwright raised its target to $115 and reiterated “buy,” Truist lifted its target to $100 and reaffirmed “buy,” and Wedbush raised its target to $91 and maintained “outperform.” The revisions signal increased analyst optimism. Wedbush price target update
- Neutral Sentiment: The company plans to submit a BLA for intermediate-risk and high-grade Ta disease in Q2 2027 and expects to complete an expanded BLA submission for BCG-unresponsive disease by the end of March 2027. These timelines offer potential catalysts, but regulatory review and approval remain ahead. Company trial and filing update
- Negative Sentiment: The Phase 3 announcement is based on topline data, which may change after full analysis. The FDA could require additional evidence, delay review, or approve a narrower label than the company expects; cretostimogene’s safety and efficacy have not yet been established by the FDA.
Analyst Upgrades and Downgrades
CGON has been the topic of a number of research analyst reports. Piper Sandler boosted their price target on CG Oncology from $82.00 to $85.00 and gave the company an "overweight" rating in a report on Friday, August 7th. HC Wainwright lifted their price objective on CG Oncology from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday. Royal Bank Of Canada cut CG Oncology from an "outperform" rating to a "sector perform" rating and boosted their target price for the company from $80.00 to $97.00 in a research note on Tuesday. Wedbush upped their target price on CG Oncology from $84.00 to $91.00 and gave the company an "outperform" rating in a report on Tuesday. Finally, Wall Street Zen raised CG Oncology from a "strong sell" rating to a "sell" rating in a research note on Saturday, November 7th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $96.11.
Get Our Latest Report on CGON
CG Oncology Trading Down 6.5%
The company has a market cap of $7.08 billion, a PE ratio of -28.70 and a beta of 0.35. The stock has a 50 day moving average price of $68.24 and a 200 day moving average price of $66.70.
CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.19. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.55 million. Equities analysts expect that CG Oncology, Inc. will post -3.00 EPS for the current fiscal year.
Insider Transactions at CG Oncology
In other news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total value of $62,060.00. Following the sale, the director directly owned 1,000 shares of the company's stock, valued at $62,060. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.80% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of CGON. WINTON GROUP Ltd bought a new position in shares of CG Oncology during the 2nd quarter worth approximately $718,000. Legal & General Group Plc acquired a new stake in CG Oncology in the second quarter worth about $2,846,000. Jefferies Financial Group Inc. purchased a new stake in shares of CG Oncology during the second quarter worth about $54,705,000. Jupiter Topco LLC acquired a new position in shares of CG Oncology during the second quarter valued at about $1,634,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of CG Oncology during the second quarter valued at about $16,584,000. 26.56% of the stock is owned by institutional investors.
About CG Oncology
(
Get Free Report)
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.